KR20080106455A - 대사장애의 조합치료 - Google Patents

대사장애의 조합치료 Download PDF

Info

Publication number
KR20080106455A
KR20080106455A KR1020087023632A KR20087023632A KR20080106455A KR 20080106455 A KR20080106455 A KR 20080106455A KR 1020087023632 A KR1020087023632 A KR 1020087023632A KR 20087023632 A KR20087023632 A KR 20087023632A KR 20080106455 A KR20080106455 A KR 20080106455A
Authority
KR
South Korea
Prior art keywords
methyl
compound
hydrogen
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087023632A
Other languages
English (en)
Korean (ko)
Inventor
보르스텔 레이드 더블유. 폰
키르빈 엘. 호지
Original Assignee
웰스태트 테러퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웰스태트 테러퓨틱스 코포레이션 filed Critical 웰스태트 테러퓨틱스 코포레이션
Publication of KR20080106455A publication Critical patent/KR20080106455A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087023632A 2006-03-31 2007-03-05 대사장애의 조합치료 Ceased KR20080106455A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74402106P 2006-03-31 2006-03-31
US60/744,021 2006-03-31

Publications (1)

Publication Number Publication Date
KR20080106455A true KR20080106455A (ko) 2008-12-05

Family

ID=38581719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087023632A Ceased KR20080106455A (ko) 2006-03-31 2007-03-05 대사장애의 조합치료

Country Status (11)

Country Link
US (1) US8338480B2 (enExample)
EP (1) EP2001461A4 (enExample)
JP (1) JP2009532372A (enExample)
KR (1) KR20080106455A (enExample)
CN (1) CN101410105A (enExample)
AU (1) AU2007235145B2 (enExample)
CA (1) CA2647258A1 (enExample)
IL (1) IL194189A0 (enExample)
MX (1) MX2008012506A (enExample)
NZ (1) NZ571118A (enExample)
WO (1) WO2007117791A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033394A3 (cs) * 2001-06-12 2005-03-16 Wellstat Therapeutics Corporation Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy
US8022249B2 (en) 2005-04-01 2011-09-20 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1978948A4 (en) * 2006-02-02 2010-06-16 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
CN101855554B (zh) * 2007-09-07 2014-05-14 儿童医院医学中心 分泌者、Lewis和唾液酸化抗原水平作为疾病预测指标的用途
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
DK2268141T3 (da) * 2008-03-13 2019-07-29 Wellstat Therapeutics Corp Forbindelse og fremgangsmåde til at reducere urinsyre
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
WO2014099285A1 (en) 2012-12-21 2014-06-26 Dolby Laboratories Licensing Corporation Object clustering for rendering object-based audio content based on perceptual criteria
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
WO2015199097A1 (ja) * 2014-06-24 2015-12-30 花王株式会社 Ｕｃｐ－１発現促進剤
JP6660668B2 (ja) * 2014-06-24 2020-03-11 花王株式会社 Ｕｃｐ−１発現促進剤
JP6553375B2 (ja) * 2014-06-24 2019-07-31 花王株式会社 Ｕｃｐ−１発現促進剤
US10758519B2 (en) 2014-06-24 2020-09-01 Kao Corporation UCP-1 expression promoter
WO2016176484A1 (en) 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
MXPA03011201A (es) * 2001-06-07 2004-02-26 Lilly Co Eli Moduladores de receptores activados por proliferadores de persoxisomas.
CZ20033394A3 (cs) 2001-06-12 2005-03-16 Wellstat Therapeutics Corporation Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy
AU2003286728A1 (en) 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2266946A3 (en) 2003-02-13 2012-12-12 Wellstat Therapeutics Corporation Compound For The Treatment Of Metabolic Disorders
DE602004030004D1 (de) 2003-04-15 2010-12-23 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US7361686B2 (en) 2003-04-22 2008-04-22 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1617835B1 (en) 2003-04-30 2011-09-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN1835743A (zh) 2003-08-20 2006-09-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
US8022249B2 (en) * 2005-04-01 2011-09-20 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2887881B1 (fr) 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
CA2636290A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
CN101410105A (zh) 2009-04-15
US8338480B2 (en) 2012-12-25
WO2007117791A3 (en) 2008-08-21
EP2001461A2 (en) 2008-12-17
EP2001461A4 (en) 2010-06-09
WO2007117791A2 (en) 2007-10-18
MX2008012506A (es) 2008-10-14
AU2007235145A1 (en) 2007-10-18
NZ571118A (en) 2011-12-22
CA2647258A1 (en) 2007-10-18
IL194189A0 (en) 2009-08-03
JP2009532372A (ja) 2009-09-10
US20100292277A1 (en) 2010-11-18
AU2007235145B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
KR20080106455A (ko) 대사장애의 조합치료
KR101934328B1 (ko) 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
CA2502297C (en) Compounds for the treatment of metabolic disorders
US8017652B2 (en) Activators of peroxisome proliferator-activated receptors
JP4804353B2 (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
AU2003299772C1 (en) Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity
ES2379165T3 (es) Uso de un agonista de PPAR-alfa para tratar la ganancia de peso asociada con un tratamiento con un agonista de PPAR-Gamma
US20060166957A1 (en) Methods of treating obesity and related disorders using tellurium selenium compounds
HK40001639B (zh) 包含阿莫地喹及抗糖尿病药物作为有效成分的用於预防或治疗糖尿病的药学组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080926

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120302

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130731

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131028

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130731

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I